According to a recent CDC study, 20.1% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities with similar numbers being reported in Europe. In 2021, the spinal cord stimulation (SCS) devices market was worth nearly $2.9 bn. Market drivers of the SCS devices market through 2026 will be driven by an aging population and an increase in selected conditions (eg back/leg pain, and a growing number of indications) that result in debilitating and unrelenting chronic pain.
In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
Sales of spinal motion preservation devices totaled $1.7bn in 2019, with sales expected to climb at a CAGR of 2.0% during 2019-2024.
An overview of primary neurological diseases/disorders treated with vagus nerve stimulation (VNS) and deep brain stimulation (DBS), as well as overview of VNS and DBS neuromodulation technologies, markets, competitors, sales and forecasts. Markets covered include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets.
This comprehensive medical market and technology report provides an overview and in-depth market analysis of devices used in the treatment of peripheral vascular disease (PVD), including peripheral arterial disease (PAD) of the lower extremities; and deep vein thrombosis (DVT) and pulmonary embolism (PE).
Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.
Sales of orthobiologics for the repair and regeneration of bone totaled nearly $2.4bn in 2018, with sales expected to climb at a CAGR of 3.2% through 2024. Growth in this market will be driven by the aging of the population and the global burden of musculoskeletal disease.
This comprehensive medical market and technology report provides an overview and in-depth market analysis of the global market for transcatheter embolization and occlusion devices.
This 8-question Pulse survey of 55 hematologic oncologists practicing throughout the United States and Europe asks respondents their thoughts on several topics presented at the 2019 American Society of Hematology (ASH) Annual Meeting. Survey questions and additional resources are listed further below.
This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes.
This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.
Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is regarded as one of the most accurate, effective, reliable, and reproducible methods of therapeutic drug and fluid delivery.
This report provides a comprehensive picture of the global medical orthopaedics market and relevant background, using the latest data and expert analysis. The report covers the top 160 markets by estimated US dollar value in 2019.
A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.
This medical market and technology report provides a comprehensive discussion of the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration (including cell-based therapies and tissue scaffolds and grafts). Geographic markets covered by this analysis include the US, Japan, five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW), which includes all other countries.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!